L

Lord Kamall (Con)

Speaking in the House of Lords on 15 June 2026

Debate

Rare Cancers: Diagnosis and Treatment

Contribution

My Lords, a number of life sciences companies have warned that the recent HMRC VAT rulings on compassionate use and early access medicine schemes, which can result in companies being charged VAT even where they provide medicines free of charge, could lead to them withdrawing programmes that provide innovative treatments to patients with rare conditions before routine NHS funding is available. Have the Government looked at the impact of charging VAT on drugs that are available for free through the compassionate use and early access schemes? What is the impact of that on their stated ambition to encourage more innovation in diagnosis and treatment of rare conditions?

More from Lord Kamall (Con)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

Partner sites